Inflammatory Breast Cancer Clinical Trial
Official title:
A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. Eribulin works by interfering with cancer cell division, growth, and spread. The goal of this research study is to evaluate inflammatory breast cancer's response to treatment with eribulin followed by AC chemotherapy (Cohort A) and also the response to treatment with AC followed by Eribulin (Cohort B) when given as a preoperative chemotherapy treatment for participants with HER2 negative inflammatory breast cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00344071 -
Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
|
N/A | |
| Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02221999 -
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT02324088 -
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
|
Phase 3 | |
| Completed |
NCT00003199 -
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
|
Phase 2 | |
| Terminated |
NCT00016276 -
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT01880385 -
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06131632 -
Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
|
N/A | |
| Completed |
NCT00513695 -
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
|
Phase 2 | |
| Completed |
NCT00340158 -
Establishing an Inflammatory Breast Cancer Registry
|
N/A | |
| Recruiting |
NCT04636710 -
Refining Local-Regional Therapy for IBC
|
N/A | |
| Active, not recruiting |
NCT05415215 -
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT04030507 -
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
|
N/A | |
| Recruiting |
NCT03515798 -
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
| Completed |
NCT01583426 -
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
|
Phase 3 | |
| Recruiting |
NCT02879513 -
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
|
Phase 3 | |
| Completed |
NCT02199418 -
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT00891280 -
Dose-escalation Study of Oral CX-4945
|
Phase 1 | |
| Completed |
NCT00049114 -
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04660929 -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
|
Phase 1 |